AABB is committed to advocating for policies that support two primary objectives: (1) ensuring that patients and health care providers have access to safe blood, transfusion medicine and biotherapies; and (2) enhancing patient and donor care and safety in transfusion medicine and biotherapies.
The 2025 Advocacy Agenda focuses on:
Northeast States Announce Public Health Collaborative
September 23, 2025
CMS to Join AABB eCast on Cellular Therapies Coding and Reimbursement
September 10, 2025
AABB, ASFA Urge CMS to Reconsider Reimbursement Policy for CAR T-Cell Therapy
September 09, 2025